{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:53:47Z","timestamp":1794243227560,"version":"4.9.0"},"reference-count":33,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0218","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T05:38:05Z","timestamp":1654666685000},"source":"Crossref","is-referenced-by-count":21,"title":["Polymyalgia rheumatica"],"prefix":"10.3238","author":[{"given":"Miriam Giovanna","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Jasmin","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Haumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudula","family":"Kirtschig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Joos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"10.3238\/arztebl.m2022.0218_ref1","doi-asserted-by":"crossref","unstructured":"Gazitt T, Zisman D, Gardner G: Polymyalgia rheumatica: a common disease in seniors. Curr Rheumatol Rep 2020; 22: 40.","DOI":"10.1007\/s11926-020-00919-2"},{"key":"10.3238\/arztebl.m2022.0218_ref2","doi-asserted-by":"crossref","unstructured":"Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C: Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging 2019; 36: 1015–26.","DOI":"10.1007\/s40266-019-00705-5"},{"key":"10.3238\/arztebl.m2022.0218_ref3","doi-asserted-by":"crossref","unstructured":"Buttgereit F, Brabant T, Dinges H, et al.: S3-Leitlinie zur Behandlung der Polymyalgia rheumatica. Z Rheumatol 2018; 77: 429–41.","DOI":"10.1007\/s00393-018-0476-8"},{"key":"10.3238\/arztebl.m2022.0218_ref4","doi-asserted-by":"crossref","unstructured":"Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul Sultan A: Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis 2018; 77: 1750–6.","DOI":"10.1136\/annrheumdis-2018-213883"},{"key":"10.3238\/arztebl.m2022.0218_ref5","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gay MA, Matteson EL, Casta\u00f1eda S: Polymyalgia rheumatica. Lancet 2017; 390: 1700–12.","DOI":"10.1016\/S0140-6736(17)31825-1"},{"key":"10.3238\/arztebl.m2022.0218_ref6","doi-asserted-by":"crossref","unstructured":"Berti A, Dejaco C: Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Pract Res Clin Rheumatol 2018; 32: 271–94.","DOI":"10.1016\/j.berh.2018.09.001"},{"key":"10.3238\/arztebl.m2022.0218_ref7","unstructured":"Bundesministerium f\u00fcr Gesundheit (BMG): Gesetzliche Krankenversicherung: Mitglieder, Angeh\u00f6rige und Krankenstand, Jahresdurchschnitt 2019. www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_JD_2019_bf.pdf (last accessed on 10 July 2021)."},{"key":"10.3238\/arztebl.m2022.0218_ref8","doi-asserted-by":"crossref","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B: Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 2016; 315: 2442–58.","DOI":"10.1001\/jama.2016.5444"},{"key":"10.3238\/arztebl.m2022.0218_ref9","doi-asserted-by":"crossref","unstructured":"Manzo C: Incidence and prevalence of polymyalgia rheumatica (PMR): the importance of the epidemiological context. The Italian case. Med Sci (Basel) 2019; 7.","DOI":"10.3390\/medsci7090092"},{"key":"10.3238\/arztebl.m2022.0218_ref10","doi-asserted-by":"crossref","unstructured":"Raheel S, Shbeeb I, Crowson CS, Matteson EL: Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res (Hoboken) 2017; 69: 1282–5.","DOI":"10.1002\/acr.23132"},{"key":"10.3238\/arztebl.m2022.0218_ref11","doi-asserted-by":"crossref","unstructured":"Bauhoff S, Fischer L, Gopffarth D, Wuppermann AC: Plan responses to diagnosis-based payment: evidence from Germany’s morbidity-based risk adjustment. J Health Econ 2017; 56: 397–413.","DOI":"10.1016\/j.jhealeco.2017.03.001"},{"key":"10.3238\/arztebl.m2022.0218_ref12","doi-asserted-by":"crossref","unstructured":"Bernatsky S, Joseph L, Pineau CA, et al.: Polymyalgia rheumatica prevalence in a population-based sample. Arthritis Rheum 2009; 61: 1264–7.","DOI":"10.1002\/art.24793"},{"key":"10.3238\/arztebl.m2022.0218_ref13","doi-asserted-by":"crossref","unstructured":"Crowson CS, Matteson EL, Myasoedova E, et al.: The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 633–9.","DOI":"10.1002\/art.30155"},{"key":"10.3238\/arztebl.m2022.0218_ref14","doi-asserted-by":"crossref","unstructured":"Carvajal Alegria G, Boukhlal S, Cornec D, Devauchelle-Pensec V: The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun Rev 2020; 19: 102670.","DOI":"10.1016\/j.autrev.2020.102670"},{"key":"10.3238\/arztebl.m2022.0218_ref15","unstructured":"Elling P, Olsson AT, Elling H: Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112–9."},{"key":"10.3238\/arztebl.m2022.0218_ref16","unstructured":"Duhaut P, Bosshard S, Calvet A, et al.: Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l’Arterite a Cellules Geantes. J Rheumatol 1999; 26: 361–9."},{"key":"10.3238\/arztebl.m2022.0218_ref17","doi-asserted-by":"crossref","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al.: Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61: 1454–61.","DOI":"10.1002\/art.24459"},{"key":"10.3238\/arztebl.m2022.0218_ref18","doi-asserted-by":"crossref","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B: The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 2017; 56: 506–15.","DOI":"10.1093\/rheumatology\/kew273"},{"key":"10.3238\/arztebl.m2022.0218_ref19","doi-asserted-by":"crossref","unstructured":"Dasgupta B, Cimmino MA, Kremers HM, et al.: 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64: 943–54.","DOI":"10.1016\/j.ymed.2012.09.009"},{"key":"10.3238\/arztebl.m2022.0218_ref20","doi-asserted-by":"crossref","unstructured":"Helliwell T, Hider SL, Mallen CD: Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract 2013; 63: e361–6.","DOI":"10.3399\/bjgp13X667231"},{"key":"10.3238\/arztebl.m2022.0218_ref21","doi-asserted-by":"crossref","unstructured":"Manzo C, Milchert M, Natale M, Brzosko M: Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. Rheumatology (Oxford) 2019; 58: 921–3.","DOI":"10.1093\/rheumatology\/key431"},{"key":"10.3238\/arztebl.m2022.0218_ref22","doi-asserted-by":"crossref","unstructured":"Cantini F, Salvarani C, Olivieri I, et al.: Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30: 17–24.","DOI":"10.1053\/sarh.2000.8366"},{"key":"10.3238\/arztebl.m2022.0218_ref23","doi-asserted-by":"crossref","unstructured":"Talke M, Schmidt WA: [Polymyalgia rheumatica in daily routine practice]. Z Rheumatol 2014; 73: 408–14.","DOI":"10.1007\/s00393-013-1344-1"},{"key":"10.3238\/arztebl.m2022.0218_ref24","doi-asserted-by":"crossref","unstructured":"Bahlas S, Ramos-Remus C, Davis P: Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clin Rheumatol 2000; 19: 278–80.","DOI":"10.1007\/s100670070045"},{"key":"10.3238\/arztebl.m2022.0218_ref25","doi-asserted-by":"crossref","unstructured":"Matteson EL, Dejaco C: Polymyalgia rheumatica. Ann Intern Med 2017; 166: ITC65–ITC80.","DOI":"10.7326\/AITC201705020"},{"key":"10.3238\/arztebl.m2022.0218_ref26","doi-asserted-by":"crossref","unstructured":"Dejaco C, Singh YP, Perel P, et al.: 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015; 74: 1799–807.","DOI":"10.1136\/annrheumdis-2015-207578"},{"key":"10.3238\/arztebl.m2022.0218_ref27","doi-asserted-by":"crossref","unstructured":"Schmidt WA: [New classification criteria for polymyalgia rheumatica]. Z Rheumatol 2012; 71: 911–2.","DOI":"10.1007\/s00393-012-1070-0"},{"key":"10.3238\/arztebl.m2022.0218_ref28","doi-asserted-by":"crossref","unstructured":"Manzo C, Natale M: Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set. Open Access Rheumatol 2016; 8: 93–5.","DOI":"10.2147\/OARRR.S116036"},{"key":"10.3238\/arztebl.m2022.0218_ref29","doi-asserted-by":"crossref","unstructured":"Partington R, Helliwell T, Muller S, Abdul Sultan A, Mallen C: Comorbidities in polymyalgia rheumatica: a systematic review. Arthritis Res Ther 2018; 20: 258.","DOI":"10.1186\/s13075-018-1757-y"},{"key":"10.3238\/arztebl.m2022.0218_ref30","doi-asserted-by":"crossref","unstructured":"Salvarani C, Cantini F, Niccoli L, et al.: Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53: 33–8.","DOI":"10.1002\/art.20901"},{"key":"10.3238\/arztebl.m2022.0218_ref31","doi-asserted-by":"crossref","unstructured":"Floris A, Piga M, Chessa E, et al.: Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol 2022; 41: 19–31.","DOI":"10.1007\/s10067-021-05819-z"},{"key":"10.3238\/arztebl.m2022.0218_ref32","doi-asserted-by":"crossref","unstructured":"Albrecht K, Huscher D, Buttgereit F, et al.: Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int 2018; 38: 569–77.","DOI":"10.1007\/s00296-017-3874-3"},{"key":"10.3238\/arztebl.m2022.0218_ref33","doi-asserted-by":"crossref","unstructured":"Manzo C, Natale M, Traini E: Diagnosis of polymyalgia rheumatica in primary health care: favoring and confounding factors – a cohort study. Reumatologia 2018; 56: 131–9.","DOI":"10.5114\/reum.2018.76900"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T05:38:26Z","timestamp":1654666706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":33,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0218","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}